Status:
TERMINATED
Incretin Physiology and Beta-cell Function Before and After Weight-loss
Lead Sponsor:
Glostrup University Hospital, Copenhagen
Collaborating Sponsors:
University of Copenhagen
European Foundation for the Study of Diabetes
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the impact of laparoscopic adjustable gastric banding (LAGB) on beta-cell function, insulin sensitivity, incretin function, postprandial secretion of incretin hormones (glucagon-like pepti...
Detailed Description
Morbid obesity represents a serious health issue in Western countries, with a rising incidence and a strong association with increased mortality and serious co-morbidities, such as diabetes. Surgical ...
Eligibility Criteria
Inclusion
- Caucasians without type 2 diabetes mellitus
- Normal OGTT (75 g of glucose) according to WHO's criteria
- Patients fulfilling the criteria for laparoscopic gastric banding
- Normal Hemoglobin
- Informed consent
Exclusion
- Liver disease (ALAT \> 2 x normal level)
- Nephropathy (s-creatinin \> 130 µM or albuminuria)
- Relatives (parents/siblings) with T2DM
- Medical treatment witch cannot be stopped for 12 hours
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00625040
Start Date
January 1 2008
End Date
January 1 2011
Last Update
October 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Glostrup Hospital
Glostrup Municipality, Denmark, 2600